1S70.F Cartesian Therapeutics, Inc.

Healthcare Biotechnology Frankfurt Exchange
5.85 EUR
Close of Nov 11, 2026
4.68 9.60
Market cap
EUR 178M
P/E
-
P/B
31.72x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 1S70.F undervalued?

Graham number

The Graham number of Cartesian Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cartesian Therapeutics, Inc. fundamental analysis

No fundamental analysis for Cartesian Therapeutics, Inc. yet.

Cartesian Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare p…

Full company profile